Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiotoxicity Mitigation and Isoform-Selective Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TOP2B drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TOP2B Full-Length & Mutant Recombinant Protein High purity (>95%), Endotoxin <1 EU/µg, Sequence Verified, ATP-binding domain intact, Theoretical MW confirmed. |
View TOP2B Products |
| Gene Delivery | TOP2B Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. HEK293 packaging, Endotoxin-free. |
View TOP2B Products |
| Benchmark Ab | Anti-TOP2B Research Grade Antibody Recombinant monoclonal for Western, ICC, and target engagement normalization. |
View TOP2B Products |
| Validator | TOP2B siRNA Set Three unique sequences for knockdown verification and assay specificity control. |
View TOP2B Products |
| Related Target A | TOP2A Primary efficacy target; mandatory selectivity counter-screen. |
View TOP2A Products |
| Related Target B | TDP2 Involved in repair of topoisomerase-mediated DNA damage. |
View TDP2 Products |
| Related Target C | TOP1 Synergistic combination therapy and broad topoisomerase panel evaluation. |
View TOP1 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (TOP2A vs TOP2B) | Purified human TOP2B & TOP2A full-length proteins with >95% purity; Sequence Verified by Mass Spec; no cross-isoform contamination. |
| ATP Competition Screening | Native ATP-binding domain conformation preserved for catalytic inhibitor development. |
| Drug Resistance Profiling | Mutant recombinant protein panel covering ATP-binding and DNA-gate variants; theoretical MW confirmed. |
| Intracellular Target Engagement | Lentivirus stable cell line system + siRNA validator set for loss-of-function control. |
| Lack of Controls | Clinical benchmark antibodies and negative control proteins included. |
| False Positives | Validated siRNA and orthogonal verification reagents. |
Live TOP2B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TOP2B therapeutics is intensifying, with a major shift from pan-topoisomerase poisons to isoform-selective strategies. Classical anthracyclines like doxorubicin cause dose-limiting cardiotoxicity by trapping TOP2B in cardiomyocytes. Next-generation approaches include catalytic inhibitors, PROTAC degraders, and TOP2B-sparing derivatives. As first-generation ADC payloads mature, emphasis is on engineered small molecules and targeted delivery to achieve an optimal therapeutic index. Emerging programs also explore TOP2B-driven transcriptional vulnerability in hematological and solid malignancies, positioning the target at the center of both safety and efficacy innovation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Catalytic Inhibitor) | Novartis, AstraZeneca, Merck, Emerging Biotech | Solid Tumors, Cardioprotection | Isoform Selectivity Assay (TOP2B vs TOP2A WT & mutant proteins) |
| Small Molecule (Poison / Dual) | Pfizer, Heritage Pharma | Breast Cancer, Lymphoma, Lung Cancer | Poisoning Assay (full-length TOP2B for cleavage complex stabilization) |
| ADC Payload Optimization | Daiichi Sankyo, Gilead | Breast Cancer, NSCLC | Toxicity profiling (pure TOP2B for payload screening) |
| PROTAC Degrader | Early-stage Biotech | AML, Prostate Cancer | Target Engagement (Lentivirus stable line + detection antibody) |
| Cardioprotectants | Dexrazoxane Developers | Anthracycline Toxicity | Target Binding Assay (native-folded recombinant protein) |
| TOP2B-Sparing Anthracycline | Academic / Biotech Innovators | Pediatric Sarcoma, Breast Cancer | Safety Counter-Screen (cardiomyocyte-relevant TOP2B protein & cell line) |
Key Functional Domains and Mutations
TOP2B (UniProt Q02880) contains two annotated functional domains: Toprim and Topo IIA-type catalytic. Key mutations include:
- p.Arg162Gln (VAR_079273): found in patients with global developmental delay and autism spectrum disorder.
- p.Lys487Ala (VAR_086569, rs2125): loss-of-function variant in yeast complementation; associated with BILU.
- p.Arg492Lys (VAR_086570): decreased protein abundance and severely reduced DNA topoisomerase type activity; associated with BILU.
These mutations are critical for resistance profiling and rational drug design. TarMart offers recombinant wild-type and mutant proteins for precise assay development.